GMAB · Genmab A/S
$32.47
+0.74% last session
End-of-day data · close of 2026-09-11
Market cap
$20B
Enterprise value
$23B
Trailing P/E
25.4
Forward P/E
20.3
Dividend yield
—
Beta
0.70
Avg volume
2M
Employees
3K
Daily Change %
0.74%
5 Days Change
-1.67%
10 Days Change
-0.36%
30 Days Change
7.10%
60 Days Change
13.93%
Month to Day Change
-0.75%
Year to Day Change
7.27%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — GMAB
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-07
Latest call per bank · past 12 months
Wells Fargo
Overweight$40.00
+24.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | Guggenheim | Maintains | Buy | $40.00 → $42.00 |
| 2026-07-22 | TD Cowen | Upgrade | Hold → Buy | $32.00 → $43.00 |
| 2026-07-02 | HC Wainwright & Co. | Maintains | Buy | $38.00 → $40.00 |
| 2026-06-23 | HC Wainwright & Co. | Reiterates | Buy | $38.00 |
| 2026-04-30 | HC Wainwright & Co. | Maintains | Buy | $40.00 → $38.00 |
| 2026-03-27 | Wolfe Research | Initiates | Outperform | $0.00 → $32.00 |
| 2026-03-02 | Wells Fargo | Initiates | Overweight | $0.00 → $40.00 |
| 2026-02-23 | Guggenheim | Maintains | Buy | $45.00 → $40.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 50 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.1% above the 50-day MA ($30.90).
- Price vs 200-day MA: Trading 10.5% above the 200-day MA ($29.39).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.32) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($23.85) and high ($35.34).
GMAB Price Chart
Loading chart for GMAB…
Fundamentals
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.